Imatinib Mesylate

newly diagnosed, chronic phase Chronic myeloid leukemia, Metastatic Gastrointestinal Stromal Tumor, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia + 20 more
Treatment
21 FDA approvals
20 Active Studies for Imatinib Mesylate

What is Imatinib Mesylate

ImatinibThe Generic name of this drug
Treatment SummaryImatinib is a cancer-fighting medicine used to treat several types of cancer. It is sold under the brand names Gleevec and Glivec. Imatinib works by blocking certain enzymes, which prevents tumor growth. This is the first drug of its kind, as it specifically targets cancer cells instead of just any rapidly dividing cells.
Gleevecis the brand name
image of different drug pills on a surface
Imatinib Mesylate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gleevec
Imatinib
2001
64

Approved as Treatment by the FDA

Imatinib, also called Gleevec, is approved by the FDA for 21 uses including Metastatic Gastrointestinal Stromal Tumor (GIST) and Blast Phase .
Metastatic Gastrointestinal Stromal Tumor (GIST)
Blast Phase
Blast Phase
Accelerated Phase Chronic Myelogenous Leukemia (CML)
recurrent Dermatofibrosarcoma protuberans
newly diagnosed, chronic phase Chronic myeloid leukemia
Myelodysplastic Syndrome
FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome
unresectable Gastrointestinal stromal tumor
metastatic Dermatofibrosarcoma protuberans
Myeloproliferative Disorders (MPD)
Metastatic Gastrointestinal Stromal Tumor
refractory, chronic phase Chronic myeloid leukemia
FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia
newly diagnosed Acute Lymphoblastic Leukaemia
Mastocytosis, Systemic
Hypereosinophilic Syndrome (HES)
Eosinophilic leukemia
Gastrointestinal Stromal Tumors
Refractory Acute Lymphoblastic Leukemia (ALL)
Leukemia, Myeloid, Accelerated Phase

Effectiveness

How Imatinib Mesylate Affects PatientsImatinib is a medicine used to treat certain types of cancer. It works by blocking the activity of certain proteins (called tyrosine kinases) that help cancer cells grow and divide. Imatinib specifically targets a protein called BCR-ABL, which is involved in many processes that cause cancer cells to grow and spread. Normal cells are usually not affected by imatinib because they have other proteins that can take over the job of the blocked protein. But cancer cells rely heavily on BCR-ABL, so they are more likely to be impacted by imatinib.
How Imatinib Mesylate works in the bodyImatinib mesylate is a drug that stops cancer cells from growing and spreading. It does this by blocking a protein called BCR-ABL, which is found in higher amounts in cancer cells. Imatinib also targets the proteins that help cancer cells survive, such as PDGF and SCF, by blocking their activity. In lab tests, imatinib has been shown to stop the growth of cancer cells and even cause them to die.

When to interrupt dosage

The measure of Imatinib Mesylate is contingent upon the determined ailment, including Metastatic Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome (HES) and Desmoid Tumors. The amount of dosage is contingent upon the method of delivery specified in the table below.
Condition
Dosage
Administration
recurrent Dermatofibrosarcoma protuberans
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Desmoid Tumors
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Hypereosinophilic Syndrome (HES)
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Refractory Acute Lymphoblastic Leukemia (ALL)
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Leukemia
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Myeloproliferative Disorders (MPD)
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Chordomas
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
allogeneic hematopoietic stem cell transplant
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
metastatic Dermatofibrosarcoma protuberans
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Myelodysplastic Syndrome
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
refractory, chronic phase Chronic myeloid leukemia
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Mastocytosis, Systemic
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Blast Phase
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Eosinophilic leukemia
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
newly diagnosed, chronic phase Chronic myeloid leukemia
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
Metastatic Gastrointestinal Stromal Tumor
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
systemic mastocytosis with associated hematological neoplasm
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution
refractory, accelerated phase Chronic myeloid leukemia
400.0 mg, , 100.0 mg, 80.0 mg/mL, 50.0 mg
Tablet, coated - Oral, , Tablet, film coated - Oral, Tablet, coated, Oral, Capsule - Oral, Tablet - Oral, Solution - Oral, Tablet, film coated, Tablet, Capsule, Solution

Warnings

Imatinib Mesylate Contraindications
Condition
Risk Level
Notes
Toxoplasma Infections
Do Not Combine
There are 20 known major drug interactions with Imatinib Mesylate.
Common Imatinib Mesylate Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Imatinib is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Imatinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Imatinib is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Imatinib is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Imatinib is combined with Aldosterone.
Imatinib Mesylate Toxicity & Overdose RiskCommon side effects of taking Voltaren include swelling, nausea, vomiting, muscle cramps, joint pain, diarrhea, rash, tiredness, and stomach pain. In animal studies, long-term use has been connected to liver, kidney, and heart damage, as well as a weakened immune system. Additionally, animals developed cardiomyopathy (heart muscle disease), chronic kidney disease, and tumors in the preputial gland. Genotoxic effects have been observed in laboratory tests. Fertility was not affected in animal studies. It is important to be aware of potential toxicities in humans, such as liver toxicity, kidney damage, cardiac
image of a doctor in a lab doing drug, clinical research

Imatinib Mesylate Novel Uses: Which Conditions Have a Clinical Trial Featuring Imatinib Mesylate?

A total of 290 active studies are presently examining the use of Imatinib Mesylate in treating Metastatic Melanoma, unresectable Gastrointestinal stromal tumor and Systemic Mastocytosis.
Condition
Clinical Trials
Trial Phases
Metastatic Melanoma
99 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1
unresectable Gastrointestinal stromal tumor
0 Actively Recruiting
Mastocytosis, Systemic
0 Actively Recruiting
Eosinophilic leukemia
1 Actively Recruiting
Phase 1
Refractory Acute Lymphoblastic Leukemia (ALL)
24 Actively Recruiting
Phase 2, Phase 1
FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia
0 Actively Recruiting
Hypereosinophilic Syndrome (HES)
0 Actively Recruiting
Myeloproliferative Disorders (MPD)
4 Actively Recruiting
Not Applicable, Phase 2, Phase 1
Myelodysplastic Syndrome
119 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Metastatic Gastrointestinal Stromal Tumor
2 Actively Recruiting
Phase 1, Phase 2
Leukemia
40 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4
newly diagnosed Acute Lymphoblastic Leukaemia
0 Actively Recruiting
Blast Phase
0 Actively Recruiting
recurrent Dermatofibrosarcoma protuberans
0 Actively Recruiting
Desmoid Tumors
5 Actively Recruiting
Phase 2, Phase 1, Phase 3
Chordomas
1 Actively Recruiting
Not Applicable
systemic mastocytosis with associated hematological neoplasm
2 Actively Recruiting
Phase 2
refractory, chronic phase Chronic myeloid leukemia
0 Actively Recruiting
newly diagnosed, chronic phase Chronic myeloid leukemia
0 Actively Recruiting
refractory, accelerated phase Chronic myeloid leukemia
0 Actively Recruiting

Imatinib Mesylate Reviews: What are patients saying about Imatinib Mesylate?

5Patient Review
7/23/2021
Imatinib Mesylate for Stromal Tumor of Stomach or Intestines
Glivec was really effective in preventing the cancer from recurring and spreading. I did experience some side effects, but overall it's a great drug that has helped me stay calm during this difficult time.
5Patient Review
4/1/2018
Imatinib Mesylate for Chronic Phase Chronic Myeloid Leukemia
The only thing I experienced were occasional skin itchings on my lower legs, which were hardly noticeable.
4Patient Review
7/28/2013
Imatinib Mesylate for Chronic Phase Chronic Myeloid Leukemia
I experienced fatigue, an increase in weight, and headaches.
3.7Patient Review
3/7/2022
Imatinib Mesylate for Chronic Phase Chronic Myeloid Leukemia
I was diagnosed with CML on March 4th, 2022 in Lusaka, Zambia. So far I've only experienced nausea, vomiting, and intense hip bone joint pain. It's been just three days of taking this medication and I feel much better already. Hoping for continued success with this treatment!
3.3Patient Review
11/11/2009
Imatinib Mesylate for Stromal Tumor of Stomach or Intestines
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about imatinib mesylate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is imatinib mesylate used for?

"Imatinib mesylate is approved to treat acute lymphoblastic leukemia in adults and children who test positive for the Philadelphia chromosome. In adults, it is used for disease that has recurred or is resistant to treatment."

Answered by AI

Is imatinib a chemotherapy?

"Imatinib, which is marketed worldwide by Novartis as Gleevec and Glivec, is an oral chemotherapy medication used to treat cancer."

Answered by AI

Is imatinib mesylate the same as imatinib?

"The drug Imatinib Mesylate is known by the trade name Gleevec and the generic name STI-571. In some cases, doctors or other health care professionals may use the trade name when referring to the generic drug."

Answered by AI

How does imatinib mesylate work?

"Imatinib works by binding to the ATP binding site, locking it in a closed or self-inhibited conformation, and inhibiting the enzyme activity of the protein. This process results in "switching off" the downstream signaling pathways that promote leukemogenesis."

Answered by AI

Clinical Trials for Imatinib Mesylate

Have you considered Imatinib Mesylate clinical trials? We made a collection of clinical trials featuring Imatinib Mesylate, we think they might fit your search criteria.
Have you considered Imatinib Mesylate clinical trials? We made a collection of clinical trials featuring Imatinib Mesylate, we think they might fit your search criteria.
Have you considered Imatinib Mesylate clinical trials? We made a collection of clinical trials featuring Imatinib Mesylate, we think they might fit your search criteria.